{"filings":[{"id":2410516,"accession_number":"0001104659-26-099712","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2026-08-21T20:31:12+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma establishes new $200M ATM offering program with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Open Market Sale Agreement with Jefferies LLC on Aug 21, 2026, for up to $200M in common stock.","Sales made via new Form S-3 shelf registration filed Aug 21, 2026; Jefferies fee up to 3.0% of gross proceeds.","Prior ATM program terminated July 20, 2026; no further sales under the Feb 13, 2026 prospectus supplement.","No minimum sales required; proceeds used for general corporate purposes, if any shares are sold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2034157,"accession_number":"0001104659-26-090094","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2026-08-04T12:25:32+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma reports Q2 2026 results; in-licenses two late-stage assets, ciprocopan approved in China, raises $115M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["In-licensed ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco; ciprocopan approved in China for PNH in July 2026.","Completed follow-on offering in July 2026 raising $115M gross proceeds, extending cash runway into 1H 2029.","Cash and equivalents $22.2M as of June 30, 2026, down from $31.6M at Dec 31, 2025.","Net loss for Q2 2026 was $7.0M vs $6.3M in Q2 2025; R&D expenses rose to $4.7M from $3.6M.","U.S. IND submission for ciprocopan expected in 4Q2026; NXP200 IND also expected in 4Q2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1361876,"accession_number":"0001104659-26-079360","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2026-06-30T20:43:15+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma prices $100M public offering of 5M shares at $20.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten public offering of 5,000,000 shares at $20.00 per share for gross proceeds of $100 million.","Net proceeds expected ~$93 million (or ~$107 million if underwriters' 30-day option for 750,000 additional shares is exercised).","Offering expected to close on July 1, 2026; Cantor Fitzgerald acting as sole book-runner.","Proceeds to fund development of NXP100, NXP200, NXP900 and for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1333198,"accession_number":"0001104659-26-078823","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2026-06-29T20:07:30+00:00","items":["8.01"],"status":"ready","headline":"Nuvectis Pharma reduces ATM capacity to $5M and suspends sales under Leerink agreement","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["On June 29, 2026, Nuvectis lowered the amount available for sale under the Sales Agreement Prospectus to $5 million.","The company is suspending the Sales Agreement Prospectus and will not sell any shares until a new prospectus or registration statement is filed.","The Sales Agreement with Leerink Partners LLC remains in full force and effect; only the current offering is paused."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1204078,"accession_number":"0001104659-26-076624","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2026-06-23T11:00:41+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nuvectis in-licenses ex-China rights to two clinical-stage compounds from Haisco for up to $1.46B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront and near-term payments total up to $40M; potential milestones up to $1.421B plus tiered royalties.","NXP100 (CFBi) has two MAAs under review in China for PNH; Ph3 ongoing in IgAN; Ph2 in LN.","NXP200 (paradox-breaker BRAFi) showed >40% response in gliomas and durable responses in multiple tumors; Phase 1b ongoing.","Deal transforms Nuvectis into late-stage clinical company with two best-in-class potential assets.","Agreement subject to financing conditions to ensure sufficient capital for product development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027283,"accession_number":"0001104659-26-073419","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2026-06-12T20:05:21+00:00","items":["5.07"],"status":"ready","headline":"Nuvectis Pharma annual meeting elects director; proxy share count corrected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proxy mistakenly stated 27,668,036 shares outstanding; correct count is 26,614,628.","Quorum of 60.8% (16,193,686 shares) present at June 11, 2026 annual meeting.","Ron Bentsur elected Class I director with 8,354,838 votes for, 391,265 against.","Kesselman & Kesselman ratified as independent auditor for FY2026 (15,662,222 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96476,"accession_number":"0001104659-26-055264","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma Q1 2026 net loss $6.1M; cash $25.1M; NXP900 Phase 1b data expected summer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $25.1M as of March 31, 2026, down from $31.6M at Dec 31, 2025.","Net loss $6.1M for Q1 2026 vs $5.3M in Q1 2025, increase driven by R&D and G&A costs.","R&D expenses $4.1M, up $0.4M YoY; G&A $2.2M, up $0.3M YoY.","NXP900 Phase 1b clinical program enrolling patients in US; monotherapy and combination arms ongoing.","Preliminary Phase 1b data readout for NXP900 expected in summer 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110409,"accession_number":"0001104659-26-013049","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma reports FY2025 net loss $26.4M; cash $31.6M; NXP900 program advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.4M for FY2025 vs $19.0M in FY2024; includes $6.0M stock-based comp and $2.4M milestone license fees.","Cash and equivalents $31.6M at Dec 31, 2025, up from $18.5M; funded by public offering and ATM facility.","R&D expenses $18.2M (up from $12.9M), G&A $9.4M (up from $6.9M); finance income $1.1M.","NXP900 Phase 1b monotherapy enrolling; combination with osimertinib (EGFR-mutated NSCLC) enrolling; lorlatinib combo pending.","CEO expects current cash to fund operations through multiple Phase 1b milestones into H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126996,"accession_number":"0001104659-25-105953","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma Q3 net loss $7.5M; cash $35.4M; NXP900 Phase 1b underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $35.4M at Sep 30, 2025, up from $18.5M at Dec 31, 2024; runway into 3Q2027.","Net loss $7.5M (Q3 2025) vs $4.2M (Q3 2024); increase driven by $2.0M NXP900 milestone expense.","R&D expenses $5.8M (Q3 2025) vs $2.8M (Q3 2024), reflecting clinical progress.","NXP900 Phase 1b single-agent portion initiated; combination arm expected by year-end 2025.","Phase 1a dose escalation and drug-drug interaction study completed with pharmacodynamic responses at clinically relevant doses."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143788,"accession_number":"0001104659-25-093144","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nuvectis Pharma appoints biotech executive Juan Sanchez, MD to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Juan Sanchez, MD appointed to board effective Sept 22, 2025; term expires at 2026 annual meeting.","Sanchez served as VP of Corp Comm & IR at Intra-Cellular Therapies, acquired by J&J for $14.6B in April 2025.","He brings 30+ years experience in biotech, capital markets, and clinical medicine.","Company plans to start Phase 1b program for NXP900, a precision oncology drug candidate.","No arrangements or family relationships; no material transactions per Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143787,"accession_number":"0001104659-25-073967","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis reports Q2 net loss of $6.3M; NXP900 Phase 1a complete; cash ~$39M proforma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.3M for Q2 2025 vs $4.4M for Q2 2024; increase driven by NXP900 DDI study and stock-based compensation.","Cash and equivalents $26.8M at June 30; after July ATM from healthcare investor, proforma ~$39M; expected to fund into 2H 2027.","NXP900 becomes lead candidate; Phase 1a dose escalation and DDI study completed; Phase 1b program initiation imminent.","NXP800 exploring opportunities in endometrial and prostate cancer; updates expected in coming months.","R&D expenses $3.6M (incl. $1.8M stock-based comp); G&A $3.0M (incl. $1.8M stock-based comp) for Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162054,"accession_number":"0001104659-25-059435","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuvectis Pharma shareholders elect director, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 14,605,167 shares (61.86%) present out of 23,606,443 outstanding shares.","Class III director James Oliviero elected with 9,882,555 votes for, 240,327 against, 782 abstentions.","Ratification of Kesselman & Kesselman as independent auditor approved with 14,561,983 votes for, 40,324 against.","All proposals passed as detailed in the April 28, 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162053,"accession_number":"0001104659-25-046845","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma establishes $60M ATM with Leerink Partners; terminates prior HC Wainwright program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New ATM agreement with Leerink Partners to sell up to $60M of common stock; 3.0% commission on gross proceeds.","Prior ATM with H.C. Wainwright for up to $40M terminated; ~$18.6M had been sold under that program.","No costs or payments associated with termination of prior ATM.","Sales will be made as at-the-market offerings on Nasdaq subject to customary conditions.","Proceeds from any sales will be used for general corporate purposes as described in the prospectus supplement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162052,"accession_number":"0001104659-25-044838","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma Q1 2025 net loss $5.3M; cash $29.9M; NXP900 Phase 1b advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $29.9M as of Mar 31, 2025, up from $18.5M at Dec 31, 2024, driven by $14.0M net public offering proceeds.","Net loss $5.3M for Q1 2025 vs $4.2M in Q1 2024; R&D expenses $3.7M, G&A $1.9M.","NXP900 Phase 1a data at AACR showed robust pharmacodynamic response; Phase 1b enrollment in specific genetic alterations pending.","NXP800 Phase 1b study in ARID1a-mutated ovarian cancer enrolling; update expected in two months.","Completed $15.5M financing extending projected cash runway into Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180084,"accession_number":"0001104659-25-016779","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma reports FY2024 net loss of $19.0M; follow-on offering extends cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $18.5M as of Dec 31, 2024, down from $19.1M; net loss $19.0M, vs $22.3M in 2023.","NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; updated data expected Q2 2025.","NXP900 Phase 1a dose escalation continues; Phase 1b program anticipated to begin mid-2025.","Follow-on offering completed Feb 2025 raised $15.5M gross, extending cash runway into 2027.","NXP800 granted Orphan Drug Designation by FDA for ARID1a-deficient ovarian, fallopian tube, and peritoneal cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180083,"accession_number":"0001104659-25-009813","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma prices $13.5M public offering at $5/share; full over-allotment exercised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 2.7M shares at $5.00 for $13.5M gross; underwriter fully exercised over-allotment of 405k shares, total gross $15.5M, net ~$14.4M.","Net proceeds to fund development of NXP800 (Phase 1b ARID1a-mutated ovarian cancer) and NXP900 (Phase 1a SRC kinase inhibitor).","Lucid Capital Markets sole book runner; offering closed February 6, 2025, after option exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196879,"accession_number":"0001104659-24-114097","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma Q3 2024 net loss $4.2M; NXP800 data update expected November","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.2M in Q3 2024 vs $5.9M Q3 2023; R&D expenses $2.8M vs $4.5M.","Cash, cash equivalents and short-term investments $17.2M as of Sep 30, 2024 (vs $19.1M Dec 31, 2023); runway into 2026.","NXP800 Phase 1b clinical data update expected November 2024; received FDA Orphan Drug Designation for ARID1a-deficient ovarian cancers.","NXP900 Phase 1a dose escalation: 4 cohorts completed with no DLTs; dose continuing; combo plans in NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213175,"accession_number":"0001104659-24-094609","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in ARID1a-deficient ovarian cancers","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug Designation for NXP800 for treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.","CEO Ron Bentsur noted prevalence exceeds 200,000 threshold; designation for a disease subset is uncommon.","Ongoing Phase 1b trial in platinum-resistant ARID1a-mutated ovarian cancer; data update expected fall 2024.","Nuvectis Pharma (NVCT) stock trades on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213174,"accession_number":"0001104659-24-086127","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Q2 2024 net loss narrows to $4.4M; progressing NXP800 and NXP900 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $18.1M at June 30, 2024, down $1.4M from March 31, 2024; net loss $4.4M vs $5.8M YoY.","R&D spend $2.9M (-33% YoY); G&A $1.7M (+13%); interest income $0.2M.","NXP800 Phase 1b ovarian cancer trial enrolling at ~15 US/UK sites; update due fall 2024.","NXP800 investigator-sponsored cholangiocarcinoma trial recruiting; update expected by end of 2024.","NXP900 dose escalation: 3 cohorts complete, no DLTs; planning combo with EGFR/ALK inhibitors in NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232295,"accession_number":"0001104659-24-071261","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuvectis Pharma stockholders re-elect directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kenneth Hoberman elected Class II director with 8,026,155 votes for, 809,797 against.","Matthew Kaplan elected Class II director with 8,502,724 votes for, 333,228 against.","Ratification of Kesselman & Kesselman as auditor approved: 12,055,252 for, 31,882 against.","Voting based on 12,227,134 shares present (66.55% of outstanding) on record date April 15, 2024.","All proposals as described in definitive proxy statement filed April 29, 2024 were approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232294,"accession_number":"0001104659-24-057782","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Q1 2024 net loss $4.2M; cash $19.5M; NXP800 Phase 1b data encouraging","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.2M in Q1 2024 vs $4.0M in Q1 2023; cash $19.5M (up from $19.1M in Dec 2023).","NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer shows encouraging preliminary data; FDA Fast Track granted.","NXP900 preclinical data at AACR: robust activity in NSCLC cell lines; synergy with alectinib and osimertinib.","R&D expense $2.7M (+$0.3M YoY); G&A $1.7M flat; interest income $0.2M (vs $0.1M).","Several clinical data updates expected in 2H 2024; cash runway estimated into 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250571,"accession_number":"0001104659-24-030773","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma FY2023 net loss $22.3M; cash $19.1M; NXP800 data update expected March 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $19.1M at Dec 31, 2023, down from $20.0M at Dec 31, 2022.","Net loss for FY2023 was $22.3M vs $19.1M in FY2022; includes $4.7M non-cash stock compensation.","R&D expenses increased to $15.4M from $13.2M; G&A increased to $7.5M from $6.0M.","NXP800 Phase 1b preliminary data update expected in March 2024 for platinum-resistant ARID1a-mutated ovarian cancer.","NXP900 Phase 1a dose escalation initiated; multiple clinical data readouts expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268119,"accession_number":"0001104659-23-115538","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis reports Q3 2023 net loss of $5.9M; cash $22.1M; NXP800 orphan drug status","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $22.1M at Sep 30, 2023, up from $20.0M at Dec 31, 2022.","Net loss $5.9M for Q3 2023, unchanged YoY; R&D expenses $4.5M.","Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer ongoing; preliminary data expected Q1 2024.","NXP900 Phase 1a dose escalation initiated in advanced solid tumors; novel preclinical data presented.","FDA granted NXP800 Orphan Drug Designation for cholangiocarcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285349,"accession_number":"0001104659-23-099872","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma initiates Phase 1a trial of NXP900 for advanced solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1a dose-escalation study evaluates safety, tolerability, and PK of NXP900 in advanced solid tumor patients.","NXP900 is a novel SRC/YES1 kinase inhibitor with low nanomolar IC50 (YES1: 0.5nM, SRC: 2.4nM).","Preclinical models showed robust single-agent anti-cancer activity across several solid tumor types.","CEO Ron Bentsur highlights NXP900's unique mechanism and target specificity versus multi-kinase inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285348,"accession_number":"0001104659-23-092871","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in cholangiocarcinoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug Designation to NXP800 for cholangiocarcinoma.","NXP800 is an oral small molecule targeting ARID1a-mutated cancers.","Phase 1b trial ongoing in ARID1a-mutated ovarian carcinoma; cholangiocarcinoma expansion planned.","CEO Ron Bentsur cites unmet medical need in cholangiocarcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285347,"accession_number":"0001104659-23-089330","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Q2 net loss $5.7M; cash $24.6M; NXP900 IND cleared, Phase 1a expected Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $24.6M at June 30, 2023, up from $20.0M at Dec 31, 2022, enough into H1 2025.","Net loss $5.7M vs $3.6M in Q2 2022; R&D expense $4.3M vs $2.5M.","NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; data expected Q1 2024.","NXP900 IND cleared by FDA; Phase 1a dose escalation study set to begin in Q3 2023.","Potential NXP800 expansion into cholangiocarcinoma supported by preclinical data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285346,"accession_number":"0001104659-23-077410","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Nuvectis Pharma reports $24.5M cash, runway into H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents of $24.5M at June 30, 2023, up ~$9.0M from March 31, 2023.","Increase primarily from exercise of previously issued preferred investment options in Q2 2023.","Company estimates current cash sufficient to fund planned operations into first half of 2025.","Cash figure is preliminary, subject to change upon completion of period-end close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305205,"accession_number":"0001104659-23-072304","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Nuvectis Pharma shareholders approve equity plan amendment increasing shares by 1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to Global Equity Incentive Plan (2021) adding 1,000,000 shares and annual evergreen from 2024-2033.","Ron Bentsur re-elected as Class I director with 9,035,321 votes for, 149,868 withheld, and 3,284,985 broker non-votes.","Ratification of Kesselman & Kesselman as independent auditor for FY 2023 approved with 12,468,118 for, 616 against, 1 abstention."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305204,"accession_number":"0001104659-23-060239","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma gets FDA clearance to begin Phase 1 trial for NXP900","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for NXP900, including Phase 1 clinical trial protocol.","NXP900 is a precision oncology drug; Nuvectis now has two clinical-stage candidates.","CEO Ron Bentsur: IND clearance is a significant milestone for corporate strategy.","NXP900 targets cancers with unmet medical need via differentiated mechanism of action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305203,"accession_number":"0001104659-23-058085","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma Q1 net loss $4.0M; initiates Phase 1b for NXP800 in ovarian cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $15.5M as of March 31, 2023 vs $20.0M at Dec 31, 2022; net loss $4.0M (Q1 2023) vs $2.9M (Q1 2022).","Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer initiated; multicenter trial with GOG Foundation and ENGOT.","IND for NXP900 pending; first-in-human trial expected shortly after IND becomes effective.","Mayo Clinic investigators presented in-vivo PDX data at AACR showing NXP800 potential in cholangiocarcinoma.","Company expects cash into H2 2024; R&D expenses $2.4M (up $0.6M YoY), G&A $1.7M (up $0.6M YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324687,"accession_number":"0001104659-23-029405","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma FY2022 net loss $19.1M; cash $20M; NXP800 Fast Track; NXP900 IND expected 1H23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $20.0M at Dec 31, 2022, up from $5.7M.","Net loss $19.1M vs $12.9M in 2021; R&D expense $13.2M; G&A $6.0M.","NXP800 granted Fast Track Designation for platinum-resistant, ARID1A-mutated ovarian cancer.","ENGOT and GOG Foundation to lead NXP800 Phase 1b trial in ovarian cancer.","NXP900 IND submission and Phase 1 start expected first half 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342508,"accession_number":"0001104659-22-115724","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma reports Q3 net loss $5.9M; provides NXP800/NXP900 clinical updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.9M for Q3 2022 vs $4.7M in Q3 2021; cash $23.6M as of Sep 30, 2022.","Phase 1a dose escalation of NXP800 ongoing; Phase 1b expansion expected to start Q1 2023.","IND-enabling studies for NXP900 ongoing; IND or equivalent submission expected Q1 2023.","Positive preclinical data for NXP800 in ARID1a-mutated gastric cancer model.","Cash runway into H2 2024; formed Scientific Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359210,"accession_number":"0001104659-22-086454","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis reports Q2 2022 net loss of $3.6M; cash $13.6M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $13.6M at June 30, 2022, up from $5.7M at Dec 31, 2021, driven by IPO.","Net loss of $3.6M for Q2 2022, narrowed from $5.9M in Q2 2021 due to lower R&D and G&A.","NXP800 Phase 1a dose-escalation ongoing; Phase 1b expansion expected Q1 2023; FDA cleared IND, U.S. and U.K. enrolling.","NXP900 IND-enabling studies on track for 2022 completion; preclinical data in medulloblastoma presented.","Completed $15.9M private placement in August 2022, extending cash runway into H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359209,"accession_number":"0001104659-22-084332","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma raises ~$15.9M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $15.9M from sale of 1,924,689 shares or pre-funded warrants at $8.25 per share plus preferred investment options.","Preferred investment options exercisable at $9.65, lockout 6 months, term 3.5 years.","H.C. Wainwright acted as placement agent with 7% cash fee plus 115,481 placement agent warrants at $10.3125.","Net proceeds intended for working capital and general corporate purposes.","Closing expected July 29, 2022, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378022,"accession_number":"0001104659-22-058628","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma Q1 net loss $2.9M; cash $16.7M; NXP800 Phase 1 dose escalation ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.9M for Q1 2022, including $0.2M non-cash expense.","Cash, cash equivalents and short-term investments of $16.7M at March 31, 2022, up from $5.7M at Dec 31, 2021 due to IPO.","R&D expenses $1.8M; G&A expenses $1.1M for the quarter.","NXP800 Phase 1 dose escalation portion ongoing; presented at 2022 AACR 'New Drugs on the Horizon'.","Completed IPO in Feb 2022 raising $16M gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396362,"accession_number":"0001104659-22-036359","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Nuvectis Pharma FY2021 net loss $12.9M; IPO raised $16M; CFO replaced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.9M for FY2021, including $7.0M upfront license payments and $1.9M non-cash equity compensation.","Cash and equivalents $5.7M at Dec 31, 2021; $16M gross IPO proceeds in Feb 2022 not included.","Phase 1a trial for NXP800 (HSF1 inhibitor) initiated Dec 2021; IND-enabling studies for NXP900 ongoing.","Michael Carson appointed VP of Finance, replacing interim CFO Uri Ben-Or; Carson is a CPA with biotech finance experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396361,"accession_number":"0001104659-22-011786","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2022-02-04T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Nuvectis Pharma prices $16M underwritten offering of 3.2M shares at $5.00; effects 39-for-1 stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $16M from sale of 3.2M shares at $5.00; expected close Feb 8, 2022.","39-for-1 stock split effective Feb 3, 2022; shares begin trading split-adjusted Feb 4, 2022.","Authorized common stock increased to 60M shares; authorized preferred stock at 5M shares.","Underwriting agreement with H.C. Wainwright & Co. as representative of underwriters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}